Related Experiment Video

Updated: Jun 28, 2025

Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells
16:24

Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells

Published on: February 21, 2014

20.2K

The regulation of microRNAs on chemoresistance in triple-negative breast cancer: a recent update

Li-Jun Yan1, Andy T Y Lau1, Yan-Ming Xu1

  • 1Laboratory of Cancer Biology & Epigenetics, Department of Cell Biology & Genetics, Shantou University Medical College, Shantou, 515041, China.

Epigenomics
|April 19, 2024
PubMed

Insights

Triple-negative breast cancer (TNBC) often resists chemotherapy due to multidrug resistance. Targeting microRNAs (miRNAs) shows promise for improving TNBC treatment outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Triple-negative breast cancer (TNBC) lacks ER, PR, and HER2 expression, necessitating chemotherapy.
  • Chemotherapy efficacy in TNBC is limited by intrinsic and acquired multidrug resistance.
  • MicroRNAs (miRNAs) are small non-coding RNAs frequently dysregulated in cancers and implicated in tumor progression.

Purpose of the Study:

  • To review and synthesize current knowledge on the role of microRNAs in chemoresistance within TNBC.
  • To highlight the potential of targeting dysregulated miRNAs for enhancing TNBC treatment strategies.

Main Methods:

  • Literature review of studies investigating microRNAs and chemoresistance in TNBC.
  • Analysis of reported associations between specific miRNA dysregulation and chemotherapy response in TNBC models and patients.

Main Results:

  • MicroRNAs are demonstrably involved in the development of chemoresistance in TNBC.
  • Dysregulation of various miRNAs contributes to both intrinsic and acquired multidrug resistance in TNBC.
  • Specific miRNAs have been identified as potential biomarkers for predicting chemoresistance.

Conclusions:

  • Targeting dysregulated miRNAs presents a promising therapeutic avenue for overcoming chemoresistance in TNBC.
  • Understanding miRNA involvement in chemoresistance can aid in developing novel diagnostic and prognostic tools for TNBC.
  • Further research into miRNA-based therapies could significantly improve treatment outcomes for TNBC patients.
Keywords:
chemoresistancemicroRNAmultidrug resistancetherapeutic targetstriple-negative breast cancer

More Related Videos

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

2.6K
Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

7.6K

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K